Scientific paper - Review paper
The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response
Current Research in Pharmacology and Drug Discovery, 2 (2021); 100064. https://doi.org/10.1016/j.crphar.2021.100064

Migo, William; Bošković, Marko; Likić, Robert

Linked objects
COVID-19 | Virtual collection
Cite this document

Migo, W., Bošković, M. & Likić, R. (2021). The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response. Current Research in Pharmacology and Drug Discovery, 2.. doi: 10.1016/j.crphar.2021.100064

Migo, William, et al. "The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response." Current Research in Pharmacology and Drug Discovery, vol. 2, 2021. https://doi.org/10.1016/j.crphar.2021.100064

Migo, William, Marko Bošković and Robert Likić. "The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response." Current Research in Pharmacology and Drug Discovery 2 (2021). https://doi.org/10.1016/j.crphar.2021.100064

Migo, W., Bošković, M. and Likić, R. (2021) 'The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response', Current Research in Pharmacology and Drug Discovery, 2. doi: 10.1016/j.crphar.2021.100064

Migo W, Bošković M, Likić R. The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response. Current Research in Pharmacology and Drug Discovery [Internet]. 2021 [cited 2024 March 29];2. doi: 10.1016/j.crphar.2021.100064

W. Migo, M. Bošković and R. Likić, "The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response", Current Research in Pharmacology and Drug Discovery, vol. 2, 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:760242. [Accessed: 29 March 2024]

Please login to the repository to save this object to your list.